Rotarix(R) Receives Favorable Recommendation From FDA Advisory Committee
AVANT Immunotherapeutics, Inc. (Nasdaq: AVAN) announced that Rotarix(R), an oral, two-dose rotavirus candidate vaccine to prevent rotavirus gastroenteritis in infants, received a favorable recommendation from the U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC). AVANT licensed the technology for Rotarix® to GlaxoSmithKline in 1997 for worldwide commercialization.
More: continued here
Filed under: GastroIntestinal / Gastroentorology on February 26th, 2008